NCT06850064

Brief Summary

Efficacy and safety of pulsed field ablation in refractory mitral isthmus-dependent atrial flutter: pulsed field ablation vs. radiofrequency ablation: a preliminary randomized controlled study

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 24, 2025

Completed
Same day until next milestone

Study Start

First participant enrolled

February 24, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 27, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

February 27, 2025

Status Verified

February 1, 2025

Enrollment Period

9 months

First QC Date

February 24, 2025

Last Update Submit

February 24, 2025

Conditions

Keywords

Mitral IsthmusPFA

Outcome Measures

Primary Outcomes (1)

  • Achieve persistent mitral isthmus block

    After mitral isthmus block, wait for 20 minutes, and obtain persistent MI block after the waiting period.

    Immediate post-operative mitral isthmus block rate.

Secondary Outcomes (2)

  • Episodes of atrial fibrillation, atrial flutter, or atrial tachycardia lasting ≥30 seconds occurred.

    During the 3-month post-operative follow-up.

  • The safety endpoint

    During the 3-month post-operative follow-up.

Study Arms (2)

Radiofrequency ablation unit

ACTIVE COMPARATOR

The patient underwent radiofrequency ablation treatment. After electrophysiological examination, radiofrequency ablation was performed.

Procedure: Radiofrequency ablation

The pulse field ablation group

EXPERIMENTAL

The pulse field ablation group will undergo pulse field ablation of the mitral valve commissure.

Procedure: Pulse Field Ablation (PFA)

Interventions

The pulse field ablation group will undergo pulse field ablation of the mitral valve commissure.

The pulse field ablation group

In the radiofrequency ablation group, patients will undergo radiofrequency ablation targeted at the mitral valve commissure.

Radiofrequency ablation unit

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged ≥18 years. 2.Diagnosed with persistent symptomatic refractory mitral valve commissural-dependent atrial flutter. Refractory mitral valve commissural-dependent atrial tachycardia is defined as:
  • Failure of drug therapy: At least one Class I or III antiarrhythmic drug (e.g., propafenone, amiodarone) fails to effectively control or prevent episodes.
  • Failure of catheter ablation: At least one previous attempt at radiofrequency catheter ablation (RFCA) targeting the mitral valve commissure has been unsuccessful (either due to recurrence post-procedure or failure to achieve bidirectional block at the commissure).
  • Intolerant to at least one antiarrhythmic drug (AAD). 4.The patient must be capable of and willing to provide written informed consent to participate in this study.

You may not qualify if:

  • Pregnant or breastfeeding women.
  • Presence of left atrial thrombus on preoperative imaging.
  • Life expectancy less than 1 year.
  • Coagulation disorders or contraindications to anticoagulant therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Chest Hospital

Shanghai, China

Location

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Irreversible Electroporation TherapyRadiofrequency Ablation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Electroporation TherapiesTherapeuticsElectroporationCytological TechniquesClinical Laboratory TechniquesInvestigative TechniquesElectrochemical TechniquesRadiofrequency TherapyAblation TechniquesSurgical Procedures, Operative

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

February 24, 2025

First Posted

February 27, 2025

Study Start

February 24, 2025

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

February 27, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations